Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

ANGLE PLC (DWV.BE)

Berlin - Berlin Delayed Price. Currency in EUR
0.6050-0.0300 (-4.72%)
At close: 08:34PM CET
Advertisement
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.6500
Open0.6400
Bid0.5600 x 0
Ask0.7050 x 0
Day's Range0.6050 - 0.6500
52 Week Range0.5350 - 1.8800
Volume144
Avg. Volume0
Market CapN/A
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for DWV.BE

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • ACCESSWIRE

      Angle PLC Announces Issue of Equity

      ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company, announces that following the exercise of employee options, it has issued and allotted 56,666 new ordinary shares of £0.10 each ("New Ordinary Shares") in the Company.

    • ACCESSWIRE

      Angle PLC Announces Multiple Downstream Analysis Techniques for CTCs

      ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company, is delighted to announce the publication of results from a multi-centre clinical study undertaken with The University of Texas MD Anderson Cancer Center, TX, Wilmot Cancer Institute, University of Rochester, NY, Robert H Lurie Comprehensive Cancer Center, Northwestern University, IL, and Norris Comprehensive Cancer Center, University of Southern California, CA, US.

    • ACCESSWIRE

      Angle PLC Announces Parsortix Poster Presented at ISLB Meeting

      ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company, is pleased to announce it presented results from a proof of concept study at the International Society of Liquid Biopsy meeting in Miami, Florida on 20-22 October 2022. The study demonstrated that both circulating tumour cells (CTCs) and cell-free circulating tumour DNA (ctDNA) can be analysed from a single blood sample.

    Advertisement
    Advertisement